VTGN
Companies
NASDAQ
VistaGen Therapeutics Inc.
Health Care
$2.06
-$0.89 (-30.17%)
Price Chart
Overview
About VTGN
we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.
Market Cap
$102.4M
Volume
387.5K
Avg. Volume
270.2K
P/E Ratio
-1.5290698
Dividend Yield
0.00%
Employees
35.0
Company Information
Latest News for VTGN
Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month - Bone Biologics (NASDAQ:BBLG), Fresh2 Group (NASDAQ:FRES)
June 21, 2023
This overlooked corner of women's health could be a $350 billion market opportunity
March 15, 2024
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates
February 13, 2025
Risk & Correlation Analysis
Market Correlation
0.77
Moderate Correlation
Volatility
High (0.68)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Low Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, VTGN shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025